NEW YORK (GenomeWeb) – Illumina announced after the close of the market Wednesday that it plans to launch a $900 million convertible senior notes offering.

The firm said it proposes to offer $450 million of notes due 2019 and $450 million in notes due 2021. In addition, it intends to grant the initial purchasers a 30-day option to purchase up to an additional $67.5 million in aggregate principal amount of the notes due 2019 and an additional $67.5 million of the notes due 2021, which would bring the total potential offering size to around $1 billion.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Consulting company McKinsey says diagnostics companies will have to combine genomic data analysis, electronic medical records, effective reimbursement strategies, and regulatory compliance in order to win.

A new report has found that researchers in Africa are still heavily dependent on funding from organizations in the US, Europe, and China, Nature News says.

An article in The Atlantic argues that the progress being made in science isn't keeping pace with the money and time being spent on research.

In Science this week: a CRISPR screen identifies sideroflexin 1 as a requisite component of one-carbon metabolism, and more.